Research n Queensland, 2009 and 2010 were epidemic years for pertussis. New patterns of disease emerged, with particularly high rates of pertussis notification for those aged 6 -< 12 years despite high primary course and booster vaccine coverage for more than a decade. A similar disease pattern was observed in California. 1 Evidence from Qld, 2 California 3-6 and Oregon 7 indicates that changing from whole-cell to acellular pertussis vaccine in the late 1990s 8, 9 contributed to recent pertussis epidemiology. In Qld and Northern California, the highest notification rates during 2010 occurred in the first birth cohorts to receive acellular pertussis vaccine. North American studies describe rapid waning of protection following a five-dose course of acellular pertussis vaccine. 4, 5, 10 Data from Qld 2 and Oregon 7 showed a primary course of whole-cell vaccine, or at least the first dose of the primary course being whole-cell vaccine, provided significantly greater protection against pertussis than priming with acellular pertussis vaccine alone. These findings are supported by earlier work from Canada, which suggests that the median time until disease following the most recent vaccine dose may be shorter in children who receive acellular pertussis vaccine compared with children who receive whole-cell pertussis vaccine. 11 Pertussis vaccination is available to children as part of the publicly funded National Immunisation Program. 8 Due to adverse events associated with the whole-cell pertussis vaccine, 12 acellular pertussis vaccine was introduced into the National Immunisation Program in 1997. The acellular vaccine (principally the threecomponent type) completely replaced the whole-cell vaccine by 1999 (Appendix 1; all appendices online at mja.com.au). 8 We sought to assess the effectiveness of acellular pertussis vaccine during 2009 and 2010 in Qld. Recog-nising the potential influence that changes in testing patterns may have on pertussis notification rates and vaccine effectiveness (VE) estimates, 13 we also investigated pertussis notification rates between 2008 and 2010 and laboratory testing patterns during 2009 and 2010 for Qld children.
Methods

Notification and testing patterns
We obtained confirmed pertussis notification data from the Qld notifiable diseases database and calculated annual age-specific notification rates for children aged 1 -< 12 years between 2008 and 2010. According to the national guidelines, pertussis case confirmation requires one of the following: definitive laboratory evidence; suggestive laboratory evidence and clinical evidence; or clinical evidence and epidemiological evidence. 14 Definitive laboratory evidence consists of Bordetella pertussis isolation by culture or detection via a nucleic acid amplification test, such as a polymerase chain reaction (PCR) assay. Suggestive laboratory evidence is most commonly met by identifying a single high serum IgA titre to pertussis antigens or evidence of seroconversion. Clinical evidence for confirmed cases requires a coughing illness lasting у 2 weeks or one of the following: coughing paroxysms, inspiratory whoop or post-tussive vomiting. Epidemiological evidence consists of contact between two people at a time when one of them is likely to be infectious and the other becomes symptomatic 6-20 days later, with at least one case in the chain of epidemiologically linked cases having been being confirmed with suggestive or definitive laboratory evidence.
Two major Qld pathology providers -Pathology Queensland, the publicly funded laboratory service, and Acellular pertussis vaccine effectiveness for children during the 2009-2010 pertussis epidemic in Queensland I Objectives: To assess the effectiveness of three, four and five doses of acellular pertussis vaccine against pertussis notification for children aged 1 -< 4 years and 5 -< 12 years, and the effectiveness of three doses of acellular pertussis vaccine against pertussis hospitalisation for children aged 1 -< 4 years.
Design, setting and participants: A population-based retrospective study of children aged 1 -< 12 years residing in Queensland, Australia, during 2009 and 2010. Routinely collected notification, hospitalisation, testing and vaccination data were used to describe notification rates and testing patterns and to assess vaccine effectiveness (VE) by the screening method. Conclusions: Acellular pertussis vaccine provided good protection within the first years of priming, but this waned as age increased. Changes in pertussis testing behaviour, because of increases in PCR use and awareness, may have contributed to increased pertussis notification rates and lower estimates of VE against notification owing to identification of milder disease.
Sullivan Nicolaides Pathology, a private company -provided data on pertussis serological tests and PCR assays undertaken at their laboratories in 2009 and 2010 for Qld resid e n t s . T he s e p rov i d e r s w e re responsible for about 40% of pertussis notifications in Qld during the study period. We did not include culture results to determine pertussis testing patterns because culture was performed infrequently and mostly on specimens also tested by PCR. We describe the numbers of serological and PCR tests, and the results of these tests, by age and year of test for children aged 1 -< 12 years.
Pertussis vaccine schedule and vaccine effectiveness
We calculated estimates of acellular pertussis VE against pertussis notification and hospitalisation in 2009 and 2010. To restrict the analysis to children who exclusively received acellular pertussis vaccine, only those residing in Qld and born in 1999 or later were included. We excluded second notifications or hospitalisations that occurred in the same individual during the same calendar year. We retrieved data on hospitalisations with a pertussis code in any diagnostic field from all Qld public and private hospitals. 15 Due to small admission numbers, VE against hospitalisation was only calculated for children VE was calculated using the screening method, which involves comparing the proportion vaccinated among people who had a case of disease (PCV) with the proportion of the study population that is vaccinated (PPV). 16 We obtained the vaccination status of patients who had a case of pertussis from Queensland Health's Vaccination Information and Vaccination Administration System. As this register does not include children who have not received any vaccines, we obtained aggregated population coverage data for Qld for each birth cohort from the national, populationbased Australian Childhood Immunisation Register (ACIR). Vaccinations recorded < 2 weeks before illness onset were excluded from calculations. The "third-dose assumption" was used in all VE calculationschildren are assumed to have received the first two doses of a three-dose course if their third dose is recorded. The validity of this assumption has been demonstrated for the ACIR. 17 Partially vaccinated children were excluded from PCV and PPV calculations. VE was not calculated for children aged < 1 or 4 -< 5 years as their vaccination status changed during the period of analysis due to receipt of the primary course or 4-year booster.
VE estimates and 95% confidence intervals were obtained by fitting logistic regression models with the outcome variable as the vaccination status of the patient with pertussis and offset for the logit of PPV. 16 We fitted constant-only models for each stratum of birth cohort and notification year. When estimating the association between birth cohort and VE, we included birth cohort as a main effect. Sensitivity analyses on diagnostic method (notified cases confirmed by PCR or culture versus all notified cases) and hospital coding (hospitalisations with a pertussis code listed as the principal diagnosis versus hospitalisations with a pertussis code in any diagnostic field) were performed. Stata version 12 (StataCorp) was used for the analysis.
Ethics approval
The Human Research Ethics Committee of Children's Health Services, Queensland Health, approved this study.
Results
Epidemiology
Pertussis notification rates increased substantially in 2009 and 2010 from pre-epidemic 2008 levels. The highest rates were in 2010, for children aged 7 -< 11 years (Box 1). 
Testing patterns
The numbers of pertussis tests performed and relative contribution of PCR tests for children aged 1 -< 12 years increased between 2009 and 2010 (Box 2). The proportions of PCR tests with a positive result were highest in the older children and increased in children aged 6 -< 12 years between 2009 and 2010 (Box 2). The proportions of serological tests with a positive result were lower, but followed a similar pattern to that for the PCR tests (Box 2).
Vaccine effectiveness
In total, 1961 pertussis notifications and 29 pertussis hospitalisations were included in the VE calculations (Appendix 2).
Notifications
In 2009 Restricting the analysis to notified cases that were cases confirmed by PCR or culture, all 2009 VE point estimates and a majority of 2010 VE estimates changed by six or fewer percentage points, and no overall consistent pattern emerged (Box 3). However, VE point estimates for several birth cohorts were substantially lower in 2010 for cases confirmed by PCR or culture. The trend of waning VE with age remained significant among cases confirmed by PCR or culture (P = 0.001 for 2009; P < 0.001 for 2010).
Hospitalisations
For children aged 1 -< 4 years, the VE estimates for the three-dose primary course against hospitalisation were 87.1% and 85.6% in 2009 and 2010, respectively (Box 3). Restricting the analysis to hospitalisations with a pertussis code in the principal diagnoses field yielded similar results.
Discussion
The primary course of acellular pertussis vaccine was highly effective in protecting children aged 1 -< 4 years against pertussis notification and hospitalisation in Qld during the epidemic years of 2009 and 2010. Our VE estimates are similar to findings for predominantly whole-cell pertussis vaccine in the late 1990s in New South Wales, where VE was 85% for children aged 2 -< 5 years. 18 However, our findings indicate that protection waned with increasing age following receipt of the 4-year booster and are consistent with the waning protection observed in the United States. 4, 5, 10 The decline in point estimates for VE against notification in 2009, from 88% in children aged 5 -< 7 years to 71% and 80% among children aged 8 -< 10 and 9 -< 11 years, respectively, is similar to 2010 findings from California, where VE progressively declined from 95% for children 1 -< 2 years after their fifth pertussis vaccine dose to 71% for children у 5 years after their fifth pertussis vaccine dose (recommended to be given at age 4-6 years). 5 Overall, higher VE estimates were found for the whole-cell pertussis vaccine in NSW between 1996 and 1998 -87% for children aged 5 -< 9 years and 78% for children aged 9 -< 14 years. 18 This is consistent with evidence showing that the whole-cell vaccine used previously in Australia provided greater duration of protection against pertussis than the acellular vaccine. Despite the waning protection provided by acellular pertussis vaccine, we should ensure that high coverage with current vaccines is maintained until low-reactogenic vaccines providing sustained high-level protection against pertussis are developed.
As the screening method is very sensitive to small changes in coverage estimates, the accuracy of PPV estimates is important. Our study benefited from obtaining PPV values from the ACIR, which registers about 99% of Australian children by 12 months of age. 19 Previous validation of ACIR data indicates that the most likely inaccuracy is that PPV will be underestimated, 20 which, in isolation, may result in underestimating VE. A limitation affecting our study is that in the context of very high vaccination cov-erage, modest changes in PCV can lead to marked changes in VE estimates. Due to regional variation in immunisation coverage (estimated to be largely < 2%), our lack of geographical stratification may have biased statewide VE estimates in either direction. In addition, the small numbers of hospitalisations provide low precision for VE estimates against severe disease. The value of this method is in providing a broad overview of VE and changes in VE over time. 21 In our study, VE point estimates were lower for 2010 compared with 2009, particularly among the older age groups. We are unable to explain the isolated low VE point estimate of 35% in 2010 among children born in 2002. While there is evidence of increasing circulation of vaccine-mismatched strains, 22 we believe vaccinedriven selection pressure is unlikely to account for such rapid and uneven changes in VE estimates between 2009 and 2010, as this would require circulating pertussis strains to vary with childhood age group and change very rapidly over time.
Changes in diagnostic testing behaviour, owing to expanded availability and increased awareness of PCR testing, 13 may have contributed to decreased VE estimates in 2010 compared with 2009. While we cannot be certain of the generalisability of the laboratory data that we used, they are probably broadly representative of pertussis testing in Qld because they accounted for about 40% of statewide pertussis notifications. Based on our 3 Vaccine coverage and vaccine effectiveness (VE) against pertussis notification and hospitalisation using the "third-dose assumption" for children aged ‡ PPV values were obtained from the Australian Childhood Immunisation Register; they were calculated by dividing numbers of fully vaccinated children in each birth cohort by total number of fully vaccinated and unvaccinated children in each birth cohort. § About one-quarter of this cohort was eligible for the 18-month booster. ¶ Principal diagnosis cases are those in which a pertussis code was listed in the principal diagnosis field. ◆ data, use of the more sensitive, less invasive PCR assays for pertussis testing has increased rapidly in Qld. Before the widespread availability of PCR assays, clinicians may have been less likely to seek laboratory confirmation involving venepuncture, particularly for milder illness in children.
Publicity about pertussis during the epidemic may have increased pertussis testing requests by clinicians; a recent study showed an almost 40% increase in testing between April 2009 to March 2010 and April 2010 to March 2011. 23 Increases in awareness, testing and detection of milder disease, and the possibility that the vaccine may be less effective against milder disease, may have resulted in decreases in VE estimates. 24 It may be hypothesised that through differential health care use, older children may be less likely to have milder disease diagnosed, leading to relatively high and stable VE estimates. However, point VE estimates among older children were substantially lower in 2010 compared with 2009. Increased testing is likely to have contributed substantially to high notification rates during the epidemic. However, the high and increasing proportion of pertussis tests with a positive result between 2009 and 2010 in older children suggests that the disease burden was truly greatest and increasing in 2010 among children aged 6 -< 12 years, consistent with notification patterns and waning protection following a four-or five-dose acellular vaccine course. A likely consequence of increased pertussis incidence among older children is increased transmission, which will have the greatest impact on infants.
In the era of predominant PCR use and heightened awareness, pertussis notification rates even during nonepidemic periods are likely to be substantially higher, and VE estimates for preventing notification may be consistently lower than recorded previously. This change in testing behaviour, leading to identification of milder disease, may require a recalibration of what are considered baseline notification rates and will need to be considered when interpreting future VE estimates.
